Beclamide

Beclamide

Beclamide
Systematic (IUPAC) name
N-benzyl-3-chloropropanamide
Clinical data
Routes of
administration
Oral
Identifiers
CAS Registry Number  Y
ATC code N03
PubChem CID:
ChemSpider  Y
UNII  Y
KEGG  Y
ChEMBL  Y
Chemical data
Formula C10H12ClNO
Molecular mass 197.661 g/mol
 Y   

Beclamide (marketed as Chloracon, Hibicon, Posedrine, Nydrane, Seclar, and other names) is a drug that possesses anticonvulsant activity.[1]

Contents

  • Uses 1
  • Side effects 2
  • Administration and pharmacology 3
  • References 4

Uses

It has been used as a sedative and as an anticonvulsant.

It was studied in the 1950s for its anticonvulsant properties, as a treatment for generalised tonic-clonic seizures. It was not effective for absence seizures. It is no longer used as an AED.

Interest in the drug resumed in the 1990s for its psychiatric properties as an adjunct in the treatment of schizophrenia.[2]

Side effects

Side effects are uncommon but include stomach pain, nervousness, giddiness, skin rash and leukopenia. It is counter-indicated in breast feeding as it is passed in the milk.

Administration and pharmacology

Administration is oral, though it has an unpleasant taste. It is quickly absorbed and elimination is renal and complete within 48 hours. Beclamide is possibly metabolized to 3-chloropropanoic acid in vivo, which binds to the GHB receptor.

References

  1. ^ Ahmadi M, Nicholls PJ, Smith HJ, Spencer PS, Preet-Ryatt MS, Spragg BP (October 1995). "Metabolism of beclamide after a single oral dose in man: quantitative studies". The Journal of pharmacy and pharmacology 47 (10): 876–8.  
  2. ^ Raptis C, Garcia-Borreguero D, Weber MM, Dose M, Bremer D, Emrich HM (February 1990). "Anticonvulsants as adjuncts for the neuroleptic treatment of schizophrenic psychoses: a clinical study with beclamide". Acta Psychiatrica Scandinavica 81 (2): 162–7.  
  • The Medical Treatment of Epilepsy by Stanley R Resor. Published by Marcel Dekker (1991). ISBN 0-8247-8549-5.